Advertisement

Topics

Cell Therapeutics Limited (UK) Company Profile

06:36 EST 25th November 2017 | BioPortfolio

At CTI, we're taking a different approach to the treatment of cancer—one focused on developing, acquiring, and commercializing therapies to combat the disease without compromising patient quality of life. Our goal is safer, more effective cancer therapies that can make a meaningful difference to millions.

Frequent conversations with medical professionals and their patients, financial analysts, media representatives and our own employees, have helped us design a Web site that we hope provides the information you seek. Our site includes general corporate information, descriptions of research advances, marketed drugs and product candidates, patient information, and career opportunities. Please explore our site to discover the innovation of our technologies and the commitment of our employees to making cancer a more treatable disease.

Location

1 Ropemaker Street
London
EC2Y 9HT
United Kingdom

Contact

Phone: +44 (0) 208 895 4004
Fax: +44 (0) 208 894 4204
Email: gacton@ctiseattle.com


News Articles [2076 Associated News Articles listed on BioPortfolio]

CRISPR Therapeutics, Neon Therapeutics partner to develop new T-cell therapies

A research collaboration was announced by CRISPR Therapeutics and Neon Therapeutics to cultivate new T-cell therapies using g -More- 

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...

Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference

Healthcare Providers, Patient Advocates, Government Agencies and Industry Will Discuss Critical Issues Facing SCD Community During National Sickle Cell Disease Awareness Month Livestream of Confe...

Amgen announces new T-cell collaboration

Will team with CytomX Therapeutics on Probody T-cell engaging bispecific

Neon Therapeutics Enters License Agreement With The Netherlands Cancer Institute (NCI) For Neoantigen-Based T Cell Therapeutics

  Life Sciences Jobs   ...

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...

EMA Says Yes To First Sickle Cell Drug For PRIME

Investigational drugs for sickle cell disease and diffuse large B cell lymphoma from Global Blood Therapeutics and Roche respectively have...   

Catalent, Grid Therapeutics in Immuno-Oncology Alliance

Will leverage GPEx cell line technology to develop cell lines and manufacture antibodies for optimization

PubMed Articles [3325 Associated PubMed Articles listed on BioPortfolio]

Mechanisms of the Amplifying Pathway of Insulin Secretion in the β Cell.

Pancreatic islet β cells secrete insulin in response to nutrient secretagogues, like glucose, dependent on calcium influx and nutrient metabolism. One of the most intriguing qualities of β cells is ...

Cancer Cell Controller.

Cancer is the disease which exists when the cell is uncontrolled. This paper presents a controller for the same. The cancer cell is reviewed via algebraic structures.

How do i participate in T-cell immunotherapy?

T cells play a key role in the adaptive immune response, and the ability to manipulate T cells for therapeutic uses has advanced in the past decade. Infusion of expanded or engineered T cells can pote...

T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics.

Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30years, ...

Tocilizumab (Actemra) for giant cell arteritis.

Clinical Trials [5469 Associated Clinical Trials listed on BioPortfolio]

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

This study evaluates the safety and clinical benefits of a therapeutics approach of conditioning regimen Cyclophosphamide (Cy) + Thymoglobulin r (ATG) + Granulocyte Colony-Stimulating Fact...

Companies [2108 Associated Companies listed on BioPortfolio]

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations ...

Stem Cell Therapeutics Corp.

Stem Cell Therapeutics is a publicly listed Canadian biotechnology company headquartered in Calgary, Alberta. The company is focused on the development and commercialization of Therapeutics that contr...

Fate Therapeutics Inc.

Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. Th...

More Information about "Cell Therapeutics Limited (UK)" on BioPortfolio

We have published hundreds of Cell Therapeutics Limited (UK) news stories on BioPortfolio along with dozens of Cell Therapeutics Limited (UK) Clinical Trials and PubMed Articles about Cell Therapeutics Limited (UK) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cell Therapeutics Limited (UK) Companies in our database. You can also find out about relevant Cell Therapeutics Limited (UK) Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record